Thursday, October 15, 2026 SourcesAbout🌓
🇺🇸 US ▾
BREAKING
› Jerry Seinfeld turns tables on radical anti-Israel agitators after chaotic Chicago stunt backfires› Dominion still has pending lawsuits against election deniers such as Rudy Giuliani and Sidney Powell› Russia is 'going backwards' in equipment and deploying post WWII-era tanks, according to Western officials› Podcast: One country musician is calling for other artists to oppose assault rifles› Bidets save you money and reduce waste — we tested the best options out there› 50+ products to make your life easier and our planet cleaner› Mother's Day is around the corner. Here are 50+ thoughtful gifts she'll love› A head-to-toe guide of how men should dress this spring, and where they should shop› 42 of the most useful travel products you can buy on Amazon› The 7 best high-yield savings accounts of April 2023› Jerry Seinfeld turns tables on radical anti-Israel agitators after chaotic Chicago stunt backfires› Dominion still has pending lawsuits against election deniers such as Rudy Giuliani and Sidney Powell› Russia is 'going backwards' in equipment and deploying post WWII-era tanks, according to Western officials› Podcast: One country musician is calling for other artists to oppose assault rifles› Bidets save you money and reduce waste — we tested the best options out there› 50+ products to make your life easier and our planet cleaner› Mother's Day is around the corner. Here are 50+ thoughtful gifts she'll love› A head-to-toe guide of how men should dress this spring, and where they should shop› 42 of the most useful travel products you can buy on Amazon› The 7 best high-yield savings accounts of April 2023
Latest

Why your health insurance is dropping GLP-1 coverage

Vox ·
Why your health insurance is dropping GLP-1 coverage

The promise of GLP-1 drugs has always depended on people being able to afford them.

These drugs still cost hundreds of dollars per month if you’re paying cash, at which point access becomes a privilege: The higher-income executive who wants to trim a few pounds might be able to afford them either way, but the low-income worker who needs the drug to lose significant weight might not be able to afford them — unless their health insurance covers it.

For a while, the trend lines for GLP-1 insurance coverage were positive.

As of 2026, roughly two-thirds of private employer plans, which insure half of Americans, were covering GLP-1 medications for weight loss to treat obesity.

Over the summer, Medicare launched a new $50-per-month prescription program.

The US has struggled with an obesity epidemic for decades, but it looked like powerful drugs to treat it were finally starting to be more seamlessly integrated into the health system.

At least that’s how things appeared earlier this year.

But now, private plans are pulling back from GLP-1 coverage.

People are being left in the lurch, debating whether to try to pay for these drugs on their own or stop taking medicines they feel are making a real difference for their health.

The dilemma reveals one of the structural flaws in American healthcare.

For working-age adults, your insurance depends on your job .

Unfortunately, because people no longer stay at the same job for decades, there is not a strong financial incentive for employers to make investments that will benefit your health in the long term — but there is a strong incentive to minimize short-term costs as much as possible.

It’s the kind of perverse rationale that could compel employer-sponsored health plans to stop covering a drug that, if taken over the full course of a person’s life, could help them not only lose weight but ultimately reduce their risk of heart disease, kidney disease and other chronic health problems , improving their health and saving all of us money as they get older.

“An employer or an insurer making coverage decisions doesn’t necessarily care if they’re saving Medicare money,” said Dan Sacks , a healthcare economist at the University of Wisconsin-Madison.

Read the full article on Vox ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.vox.com — the content belongs to Vox.

More from Vox

See all ›

More in Latest

See all ›